Framework Ventures IV L.P. sold $27k of SDEV
owner at NovaBay Pharmaceuticals, Inc.. 24,720 shares at an average of $1.09, traded Jun 15, 2026, filed Jun 17, 2026.
Score components
- +12Role10% owner
- +5Trade size$27k at market
- 0Share of holdings soldSold 0.1% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-26-021025, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 15, 2026 | XIn-the-money exercise Common Stock | +11,332,020 | $0.00 | $27k | 22,693,236 | Jun 17, 2026 |
| Jun 15, 2026 | SOpen-market sale Common Stock | -24,720 | $1.09 | $27k | 22,668,516 | Jun 17, 2026 |
| Jun 15, 2026 | XIn-the-money exercise Pre-Funded Warrants (Right to Buy)derivative | +11,332,020 | $0.00 | $0 | 0 | Jun 17, 2026 |
Related signals
Other insiders at NovaBay Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | NovaBay Pharmaceuticals, Inc. | Michael John Kazley Chief Executive Officer | $27k 24,720 shares | -0% | |
| 38Weak | NovaBay Pharmaceuticals, Inc. | Michael John Kazley Chief Executive Officer | $27k 24,720 shares | -0% | |
| 18Weak | SDEVbuy NovaBay Pharmaceuticals, Inc. | Poplar Point Capital Partners LP owner | $68k 102,388 shares | +20% | |
| 22Weak | SDEVbuy NovaBay Pharmaceuticals, Inc. | Poplar Point Capital Partners LP owner | $56k 84,487 shares | +14% | |
| 20Weak | SDEVbuy NovaBay Pharmaceuticals, Inc. | Poplar Point Capital Partners LP owner | $30k 48,930 shares | +7% | |
| 21Weak | SDEVbuy NovaBay Pharmaceuticals, Inc. | Poplar Point Capital Partners LP owner | $40k 64,175 shares | +9% | |
| 20Weak | SDEVbuy NovaBay Pharmaceuticals, Inc. | Poplar Point Capital Partners LP owner | $31k 49,927 shares | +6% | |
| 23Weak | SDEVbuy NovaBay Pharmaceuticals, Inc. | Poplar Point Capital Partners LP owner | $75k 123,365 shares | +14% | |
| 12Weak | SDEVbuy NovaBay Pharmaceuticals, Inc. | Poplar Point Capital Partners LP owner | $16k 28,731 shares | +3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.